Efficacy of Adjunctive Infliximab vs Placebo in the Treatment of Adults with Bipolar I/II Depression: A Randomized Clinical Trial

JAMA Psychiatry

Volumn 76, Issue 8, 2019, Pages 783-790

  McIntyre, Roger S ^a,b,c   Subramaniapillai, Mehala ^a   Lee, Yena ^a,b   Pan, Zihang ^a,b   Carmona, Nicole E ^a   Shekotikhina, Margarita ^a,d   Rosenblat, Joshua D ^a,c   Brietzke, Elisa ^a,e   Soczynska, Joanna K ^a   Cosgrove, Victoria E ^f   Miller, Shefali ^f   Fischer, Eileen Grace ^f   Kramer, Nicole E ^f   Dunlap, Kiley ^f   Suppes, Trisha ^f   Mansur, Rodrigo B ^a,c  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INFLIXIMAB; PLACEBO; ANTIDEPRESSANT AGENT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTHRITIS; ARTICLE; BIOCHEMICAL ANALYSIS; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BRAIN INJURY; CANADA; CHILD ABUSE; CHILDHOOD TRAUMA QUESTIONNAIRE; CLINICAL FEATURE; CONTROLLED STUDY; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-5; FEMALE; HAIR LOSS; HUMAN; INFLAMMATION; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; OUTPATIENT; PHENOTYPE; PHYSICAL ABUSE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES; BIPOLAR DISORDER; CHILD ABUSE SURVIVOR; CLINICAL TRIAL; COMPLICATION; DEPRESSION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY;

ADULT; ADULT SURVIVORS OF CHILD ABUSE; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLIXIMAB; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT, HEALTH CARE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85065577043     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2019.0779     Document Type: Article

References (33)

1. Judd LL, Akiskal HS, Schettler PJ, The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry. 2002; 59 (6): 530-537. doi: 10.1001/archpsyc.59.6.530 12044195
2. Insel PA, Amara SG, Blaschke TF. Introduction to the theme "precision medicine and prediction in pharmacology." Annu Rev Pharmacol Toxicol. 2015; 55: 11-14. doi: 10.1146/annurev-pharmtox-101714-123102 25562643
3. Subramaniapillai M, Carmona NE, Rong C, McIntyre RS. Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders. Dialogues Clin Neurosci. 2017; 19 (1): 27-36. 28566945
4. Passos IC, Vasconcelos-Moreno MP, Costa LG, Inflammatory markers in post-traumatic stress disorder: a systematic review, meta-analysis, and meta-regression. Lancet Psychiatry. 2015; 2 (11): 1002-1012. doi: 10.1016/S2215-0366(15)00309-0 26544749
5. Aas M, Dieset I, Hope S, Childhood maltreatment severity is associated with elevated C-reactive protein and body mass index in adults with schizophrenia and bipolar diagnoses. Brain Behav Immun. 2017; 65: 342-349. doi: 10.1016/j.bbi.2017.06.005 28619247
6. Rosenblat JD, Kakar R, Berk M, Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord. 2016; 18 (2): 89-101. doi: 10.1111/bdi.12373 26990051
7. Kappelmann N, Lewis G, Dantzer R, Jones PB, Khandaker GM. Antidepressant activity of anti-cytokine treatment: a systematic review and meta-analysis of clinical trials of chronic inflammatory conditions. Mol Psychiatry. 2018; 23 (2): 335-343. doi: 10.1038/mp.2016.167 27752078
8. Raison CL, Rutherford RE, Woolwine BJ, A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013; 70 (1): 31-41. doi: 10.1001/2013.jamapsychiatry.4 22945416
9. Felger JC, Haroon E, Patel TA, What does plasma CRP tell us about peripheral and central inflammation in depression? [published online June 12, 2018]. Mol Psychiatry. 29895893
10. Karabulut KU, Egercioglu TU, Uyar M, Ucar Y. The change of neutrophils/lymphocytes ratio in migraine attacks: a case-controlled study. Ann Med Surg (Lond). 2016; 10: 52-56. doi: 10.1016/j.amsu.2016.07.023 27551404
11. Sarchielli P, Alberti A, Baldi A, Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006; 46 (2): 200-207. doi: 10.1111/j.1526-4610.2006.00337.x 16492228
12. International Headache Society. ICHD/Guidelines. https://www.ihs-headache.org/ichd-guidelines. Accessed on April 1, 2018.
13. Cheng AY; Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada: introduction. Can J Diabetes. 2013; 37 (suppl 1): S1-S3. doi: 10.1016/j.jcjd.2013.01.009 24070926
14. Rosenblat JD, Gregory JM, McIntyre RS. Pharmacologic implications of inflammatory comorbidity in bipolar disorder. Curr Opin Pharmacol. 2016; 29: 63-69. doi: 10.1016/j.coph.2016.06.007 27400335
15. Etain B, Lajnef M, Brichant-Petitjean C, Childhood trauma and mixed episodes are associated with poor response to lithium in bipolar disorders. Acta Psychiatr Scand. 2017; 135 (4): 319-327. doi: 10.1111/acps.12684 27987204
16. Walker EA, Gelfand A, Katon WJ, Adult health status of women with histories of childhood abuse and neglect. Am J Med. 1999; 107 (4): 332-339. doi: 10.1016/S0002-9343(99)00235-1 10527034
17. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996; 11 (suppl 3): 89-95. doi: 10.1097/00004850-199606003-00015 8923116
18. Hawley CJ, Gale TM, Sivakumaran T; Hertfordshire Neuroscience Research Group. Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72 (2): 177-184. doi: 10.1016/S0165-0327(01)00451-7 12200208
19. Cohen-Woods S, Fisher HL, Ahmetspahic D, Interaction between childhood maltreatment on immunogenetic risk in depression: discovery and replication in clinical case-control samples. Brain Behav Immun. 2018; 67: 203-210. doi: 10.1016/j.bbi.2017.08.023 28867280
20. Baumeister D, Akhtar R, Ciufolini S, Pariante CM, Mondelli V. Childhood trauma and adulthood inflammation: a meta-analysis of peripheral C-reactive protein, interleukin-6 and tumour necrosis factor-α. Mol Psychiatry. 2016; 21 (5): 642-649. doi: 10.1038/mp.2015.67 26033244
21. Coelho R, Viola TW, Walss-Bass C, Brietzke E, Grassi-Oliveira R. Childhood maltreatment and inflammatory markers: a systematic review. Acta Psychiatr Scand. 2014; 129 (3): 180-192. doi: 10.1111/acps.12217 24205846
22. Pedrotti Moreira F, Wiener CD, Jansen K, Childhood trauma and increased peripheral cytokines in young adults with major depressive: population-based study [published online February 28, 2018]. J Neuroimmunol. 2018; 319: 112-116. doi: 10.1016/j.jneuroim.2018.02.018 29519722
23. Danese A, Moffitt TE, Harrington H, Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Arch Pediatr Adolesc Med. 2009; 163 (12): 1135-1143. doi: 10.1001/archpediatrics.2009.214 19996051
24. Grosse L, Ambrée O, Jörgens S, Cytokine levels in major depression are related to childhood trauma but not to recent stressors. Psychoneuroendocrinology. 2016; 73: 24-31. doi: 10.1016/j.psyneuen.2016.07.205 27448525
25. Daruy-Filho L, Brietzke E, Lafer B, Grassi-Oliveira R. Childhood maltreatment and clinical outcomes of bipolar disorder [published online November 3, 2017]. Acta Psychiatr Scand. 2011; 124 (6): 427-434. doi: 10.1111/j.1600-0447.2011.01756.x 21848703
26. Kane JC, Murray LK, Cohen J, Moderators of treatment response to trauma-focused cognitive behavioral therapy among youth in Zambia. J Child Psychol Psychiatry. 2016; 57 (10): 1194-1202. doi: 10.1111/jcpp.12623 27647052
27. Danese A, Moffitt TE, Pariante CM, Ambler A, Poulton R, Caspi A. Elevated inflammation levels in depressed adults with a history of childhood maltreatment. Arch Gen Psychiatry. 2008; 65 (4): 409-415. doi: 10.1001/archpsyc.65.4.409 18391129
28. Goldstein BI, Carnethon MR, Matthews KA,; American Heart Association Atherosclerosis; Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2015; 132 (10): 965-986. doi: 10.1161/CIR.0000000000000229 26260736
29. Köhler CA, Freitas TH, Maes M, Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand. 2017; 135 (5): 373-387. doi: 10.1111/acps.12698 28122130
30. Köhler CA, Freitas TH, Stubbs B, Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol. 2018; 55 (5): 4195-4206. 28612257
31. Marrie RA, Walld R, Bolton JM,; CIHR Team in Defining the Burden and Managing the Effects of Psychiatric Comorbidity in Chronic Immunoinflammatory Disease. Rising incidence of psychiatric disorders before diagnosis of immune-mediated inflammatory disease. Epidemiol Psychiatr Sci. 2017: 1-10. doi: 10.1017/S2045796017000579 29098977
32. Leighton SP, Nerurkar L, Krishnadas R, Johnman C, Graham GJ, Cavanagh J. Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2018; 23 (1): 48-58. doi: 10.1038/mp.2017.205 29133955
33. Nierenberg AA, Østergaard SD, Iovieno N, Walker RS, Fava M, Papakostas GI. Predictors of placebo response in bipolar depression. Int Clin Psychopharmacol. 2015; 30 (2): 59-66. doi: 10.1097/YIC.0000000000000058 25438027